Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.

Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM, Jayashankar L, Miotto P, Zignol M, Schito M.

Clin Infect Dis. 2019 Mar 18. pii: ciz219. doi: 10.1093/cid/ciz219. [Epub ahead of print]

PMID:
30883637
2.

Casting a wider net: Immunosurveillance by nonclassical MHC molecules.

D'Souza MP, Adams E, Altman JD, Birnbaum ME, Boggiano C, Casorati G, Chien YH, Conley A, Eckle SBG, Früh K, Gondré-Lewis T, Hassan N, Huang H, Jayashankar L, Kasmar AG, Kunwar N, Lavelle J, Lewinsohn DM, Moody B, Picker L, Ramachandra L, Shastri N, Parham P, McMichael AJ, Yewdell JW.

PLoS Pathog. 2019 Feb 21;15(2):e1007567. doi: 10.1371/journal.ppat.1007567. eCollection 2019 Feb. Review.

3.

Eliminating perinatal HIV in the United States: mission possible?

Gnanashanmugam D, Rakhmanina N, Crawford KW, Nesheim S, Ruel T, Birkhead GS, Chakraborty R, Lawrence R, Jean-Philippe P, Jayashankar L, Hoover A, Statton A, DʼSouza P, Fitzgibbon J, Hazra R, Warren B, Smith S, Abrams EJ.

AIDS. 2019 Mar 1;33(3):377-385. doi: 10.1097/QAD.0000000000002080.

PMID:
30475262
4.

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team.

NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018.

5.

Tuberculous meningitis: a roadmap for advancing basic and translational research.

Jain SK, Tobin DM, Tucker EW, Venketaraman V, Ordonez AA, Jayashankar L, Siddiqi OK, Hammoud DA, Prasadarao NV, Sandor M, Hafner R, Fabry Z; NIH Tuberculous Meningitis Writing Group.

Nat Immunol. 2018 Jun;19(6):521-525. doi: 10.1038/s41590-018-0119-x. No abstract available.

6.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
7.

HIV birth testing and linkage to care for HIV-infected infants.

Jean-Philippe P, Spiegel H, Gnanashanmugam D, Fitzgibbon J, DʼSouza P, Crawford KW, Jayashankar L, Bacon MC, Essajee SM, Aldrovandi GM, Cotton M, Abrams EJ.

AIDS. 2017 Aug 24;31(13):1797-1807. doi: 10.1097/QAD.0000000000001561.

PMID:
28590330
8.

Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination.

Jayashankar L, Hafner R.

Front Immunol. 2016 Dec 16;7:577. doi: 10.3389/fimmu.2016.00577. eCollection 2016. Review.

9.

Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults.

Santini-Oliveira M, Coler RN, Parra J, Veloso V, Jayashankar L, Pinto PM, Ciol MA, Bergquist R, Reed SG, Tendler M.

Vaccine. 2016 Jan 20;34(4):586-594. doi: 10.1016/j.vaccine.2015.10.027. Epub 2015 Nov 10.

PMID:
26571311
10.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

11.

5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication.

Ranjan P, Jayashankar L, Deyde V, Zeng H, Davis WG, Pearce MB, Bowzard JB, Hoelscher MA, Jeisy-Scott V, Wiens ME, Gangappa S, Gubareva L, García-Sastre A, Katz JM, Tumpey TM, Fujita T, Sambhara S.

Virol J. 2010 May 21;7:102. doi: 10.1186/1743-422X-7-102.

12.

Vaccines against epidemic and pandemic influenza.

Hoelscher M, Gangappa S, Zhong W, Jayashankar L, Sambhara S.

Expert Opin Drug Deliv. 2008 Oct;5(10):1139-57. doi: 10.1517/17425247.5.10.1139 . Review. Erratum in: Expert Opin Drug Deliv. 2009 Feb;6(2):209.

PMID:
18817518
13.

A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.

Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, Pandey A, Matsuoka Y, Katz JM, Donis R, Mittal SK, Sambhara S.

J Infect Dis. 2008 Apr 15;197(8):1185-8. doi: 10.1086/529522.

14.

Nonhuman primate IgA: genetic heterogeneity and interactions with CD89.

Rogers KA, Jayashankar L, Scinicariello F, Attanasio R.

J Immunol. 2008 Apr 1;180(7):4816-24.

15.

Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.

Singh N, Pandey A, Jayashankar L, Mittal SK.

Mol Ther. 2008 May;16(5):965-71. doi: 10.1038/mt.2008.12. Epub 2008 Feb 26.

16.

New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

Hoelscher MA, Jayashankar L, Garg S, Veguilla V, Lu X, Singh N, Katz JM, Mittal SK, Sambhara S.

Clin Pharmacol Ther. 2007 Dec;82(6):665-71. Epub 2007 Oct 24.

17.

Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.

Garg S, Hoelscher M, Belser JA, Wang C, Jayashankar L, Guo Z, Durland RH, Katz JM, Sambhara S.

Clin Vaccine Immunol. 2007 Jul;14(7):926-8. Epub 2007 May 9.

18.

Sooty mangabey (Cercocebus torquatus atys) IGHG and IGHA genes.

Scinicariello F, Masseoud F, Jayashankar L, Attanasio R.

Immunogenetics. 2006 Dec;58(12):955-65. Epub 2006 Oct 18.

PMID:
17048039
19.

A distal regulatory region is required for constitutive and IFN-beta-induced expression of murine TLR9 gene.

Guo Z, Garg S, Hill KM, Jayashankar L, Mooney MR, Hoelscher M, Katz JM, Boss JM, Sambhara S.

J Immunol. 2005 Dec 1;175(11):7407-18.

20.

Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions.

Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R.

Immunology. 2004 Jan;111(1):66-74.

21.

Lymphocyte modulation in a baboon model of immunosenescence.

Jayashankar L, Brasky KM, Ward JA, Attanasio R.

Clin Diagn Lab Immunol. 2003 Sep;10(5):870-5.

22.

Baboon immunoglobulin constant region heavy chains: identification of four IGHG genes.

Attanasio R, Jayashankar L, Engleman CN, Scinicariello F.

Immunogenetics. 2002 Nov;54(8):556-61. Epub 2002 Oct 24.

PMID:
12439618
23.

Baboon immunoglobulin variable region heavy chains: identification of genes homologous to members of the human IGHV1-IGHV7 subgroups.

Scinicariello F, Jayashankar L, Attanasio R.

Immunogenetics. 2002 Feb;53(10-11):815-20. Epub 2002 Feb 1.

PMID:
11862381
24.

Age-related autoantibody production in a nonhuman primate model.

Attanasio R, Brasky KM, Robbins SH, Jayashankar L, Nash RJ, Butler TM.

Clin Exp Immunol. 2001 Mar;123(3):361-5.

Supplemental Content

Loading ...
Support Center